Several reports indicate that high expression of TGF-β target genes and mesenchymal subtypes correlate with poor prognosis in patients with many different cancer types, including CRC, hepatocellular carcinoma, and lung cancer [44,45,46]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.